Accueil > BIGG > Résultat de la recherche

    Résultats: 2

    Systemic therapy for melanoma: ASCO guideline update

    Seth, Rahul; Agarwala, Sanjiv S; Messersmith, Hans; Alluri, Krishna C; Ascierto, Paolo A; Atkins, Michael B; Bollin, Kathryn; Chacon, Matias; Davis, Nancy; Faries, Mark B; Funchain, Pauline; Gold, Jason S; Guild, Samantha; Gyorki, David E; Kaur, Varinder; Khushalani, Nikhil I; Kirkwood, John M; McQuade, Jennifer Leigh; Meyers, Michael O; Provenzano, Anthony; Robert, Caroline; Santinami, Mario; Sehdev, Amikar; Sondak, Vernon K; Spurrier, Gilliosa; Swami, Umang; Truong, Thach-Giao; Tsai, Katy K; van Akkooi, Alexander; Weber, Jeffrey.
    J. clin. oncol; 41 (30), 2023
    To provide guidance to clinicians regarding the use of systemic therapy for melanoma. American Society of Clinical Oncology convened an Expert Panel and conducted an updated systematic review of the literature. The updated review identified 21 additional randomized trials. Neoadjuvant pembrolizumab was n...
    Mélanome/immunologie, Nivolumab/usage thérapeutique, Antinéoplasiques immunologiques, Mutation/immunologie
    Texte intégral

    Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma

    England. National Institute for Health and Care Excellence.
    Next Evidence-based recommendations on nivolumab (Opdivo) with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma in adults. Commercial arrangement There is a commercial access agreement for nivolumab...
    Nivolumab/usage thérapeutique, Antimétabolites/usage thérapeutique, Inhibiteurs de points de contrôle immunitaires/usage thérapeutique, Tumeurs de l'oesophage/thérapie, Métastase tumorale/prévention et contrôle
    Texte intégral (lien principal)     Texte intégral (lien alternatif)